JP2017538446A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538446A5
JP2017538446A5 JP2017547931A JP2017547931A JP2017538446A5 JP 2017538446 A5 JP2017538446 A5 JP 2017538446A5 JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017547931 A JP2017547931 A JP 2017547931A JP 2017538446 A5 JP2017538446 A5 JP 2017538446A5
Authority
JP
Japan
Prior art keywords
recombinant protein
perfusion
mammalian host
bioreactor
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017547931A
Other languages
English (en)
Japanese (ja)
Other versions
JP6698681B2 (ja
JP2017538446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063271 external-priority patent/WO2016089919A1/en
Publication of JP2017538446A publication Critical patent/JP2017538446A/ja
Publication of JP2017538446A5 publication Critical patent/JP2017538446A5/ja
Application granted granted Critical
Publication of JP6698681B2 publication Critical patent/JP6698681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017547931A 2014-12-01 2015-12-01 糖タンパク質のグリカン含量のレベルを操作するためのプロセス Active JP6698681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
US62/085,759 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080270A Division JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Publications (3)

Publication Number Publication Date
JP2017538446A JP2017538446A (ja) 2017-12-28
JP2017538446A5 true JP2017538446A5 (https=) 2019-01-17
JP6698681B2 JP6698681B2 (ja) 2020-05-27

Family

ID=55024253

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017547931A Active JP6698681B2 (ja) 2014-12-01 2015-12-01 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2020080270A Active JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2022072126A Pending JP2022101669A (ja) 2014-12-01 2022-04-26 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2024063188A Pending JP2024095777A (ja) 2014-12-01 2024-04-10 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020080270A Active JP7066775B2 (ja) 2014-12-01 2020-04-30 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2022072126A Pending JP2022101669A (ja) 2014-12-01 2022-04-26 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2024063188A Pending JP2024095777A (ja) 2014-12-01 2024-04-10 糖タンパク質のグリカン含量のレベルを操作するためのプロセス

Country Status (22)

Country Link
US (6) US10167492B2 (https=)
EP (2) EP3227454B1 (https=)
JP (4) JP6698681B2 (https=)
KR (1) KR102623965B1 (https=)
CN (1) CN107109455B (https=)
AU (5) AU2015355087C1 (https=)
CA (1) CA2969225C (https=)
CL (1) CL2017001369A1 (https=)
CY (1) CY1123247T1 (https=)
DK (1) DK3227454T3 (https=)
EA (2) EA036178B1 (https=)
ES (1) ES2784503T3 (https=)
HU (1) HUE049201T2 (https=)
IL (2) IL276165B (https=)
LT (1) LT3227454T (https=)
MX (1) MX385409B (https=)
PL (1) PL3227454T3 (https=)
PT (1) PT3227454T (https=)
SG (2) SG10202002458PA (https=)
SI (1) SI3227454T1 (https=)
WO (1) WO2016089919A1 (https=)
ZA (2) ZA201703729B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
EP3397282A4 (en) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS RELATING TO BIOLOGICA
AU2018235928B2 (en) * 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
AU2018241849B2 (en) * 2017-03-31 2023-06-22 Boehringer Ingelheim International Gmbh Perfusion medium
WO2019105444A1 (zh) * 2017-11-30 2019-06-06 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
AU2019274782A1 (en) * 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
US20210155710A1 (en) 2018-06-05 2021-05-27 Amgen Inc. Modulating antibody dependent cellular phagocytosis
AU2019336148B2 (en) 2018-09-06 2025-08-14 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EA202191352A1 (ru) 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
WO2020142275A1 (en) * 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
CA3127228A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
AU2020268442A1 (en) 2019-05-06 2021-11-25 One Amgen Center Drive Law - Patent Operations Modulating antibody effector functions
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
US12529024B2 (en) 2019-11-15 2026-01-20 Lonza Ltd Process and system for producing an inoculum
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2023223660A1 (en) * 2022-02-25 2024-08-01 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
CN121712803A (zh) * 2023-08-16 2026-03-20 葛兰素史密斯克莱知识产权有限公司 控制抗体糖基化谱的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP3029062A1 (en) 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008121757A1 (en) * 2007-03-30 2008-10-09 Centocor Inc High expression clones of mammalian cells with fluorescent protein a or g
EP2528002B1 (en) 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
PT2173861E (pt) 2007-06-15 2011-05-13 Amgen Inc M?todos de tratamento de meios de cultura de c?lulas para utiliza??o num biorreactor
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120164137A1 (en) * 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
KR20130129438A (ko) 2011-02-23 2013-11-28 암젠 인크 Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법
WO2012120500A2 (en) * 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
DK2726600T3 (en) 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
TWI583788B (zh) 2011-09-16 2017-05-21 安美基公司 細胞培養之預程式化無回饋控制之連續進料
EA201992617A1 (ru) 2011-10-26 2020-03-10 Амген Инк. Способы уменьшения или устранения модификации и разложения белка, обусловленных воздействием уф-излучения
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
US9714291B2 (en) * 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR102062784B1 (ko) 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
HRP20200100T1 (hr) * 2014-02-27 2020-04-03 F. Hoffmann - La Roche Ag Modulacija rasta i glikozilacije stanica u rekombinantnoj proizvodnji glikoproteina
SG11201702964UA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína

Similar Documents

Publication Publication Date Title
JP2017538446A5 (https=)
IL310968B1 (en) Mammalian cell culture
Matanguihan et al. Upstream continuous processing: recent advances in production of biopharmaceuticals and challenges in manufacturing
JP2019514411A5 (https=)
JP2017501749A5 (https=)
RU2013152982A (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
CN102154189B (zh) 一种rhG-CSF重组工程菌的发酵培养方法
CN116083344A (zh) 对连续流动搅拌釜反应器细胞培养系统的连接灌注
CN103320390A (zh) 一种大规模哺乳动物工程细胞培养方法
JP2010110331A5 (https=)
JP2015532096A5 (https=)
JP2012519485A5 (https=)
TW202328427A (zh) 超高密度細胞儲存方法
CN103773741A (zh) 笼式通气搅拌生物反应器制备流感疫苗的方法
CN102382794B (zh) 一种哺乳动物细胞的灌流培养方法
CN106222129A (zh) 一种提高抗体纯度的细胞培养基和培养方法
KR20200128108A (ko) 생물 대분자 업스트림 단계별 차단의 생산 방법, 생산 모듈 및 생산에서의 응용
CN114127260A (zh) 高密度连续接种的细胞培养方法及其应用
CN107299078A (zh) 一株适应全悬浮培养的猫肾细胞系f‑81 s及其应用
IL307155B1 (en) Antibodies with modulated glycan profiles
CN109628407A (zh) 高密度长期培养表达抗vegf人源化单克隆抗体重组cho细胞的方法
CN104982321B (zh) 一种马铃薯脱毒苗叠式培养盘及其使用方法
CN109134645A (zh) 一种细胞浓缩补料培养工艺
JP2016534755A5 (https=)
CN101838661B (zh) 一种高稳定性藻蓝蛋白类融合荧光蛋白质的制备方法